Items tagged with Diagnostics
A timely triage test for TB (post)
More than 10 million people around the world have active tuberculosis (ATB), and every year more than a million die from it. The majority of patients live in low-resource countries where diagnosing ATB is especially challenging, as newer tests require expensive lab equipment that is frequently not available, and the historic standard of culturing a sputum sample is slow and often not sensitive enough to correctly identify ATB, meaning that many patients whose disease needs treatment are not identified until it is too late.
From ancient tools to artificial intelligence for TB detection and intelligence (post)
23 October 2019, Geneva, Switzerland. Artificial intelligence (AI), a buzzword in the tech world, has steadily marked its presence in the field of healthcare, including in tuberculosis (TB). Recently, AI is being employed to read and screen chest x-rays for TB. These new solutions are providing hope to tackle TB, which kills more people worldwide than any single infectious disease. The Stop TB Partnership’s TB REACH is leading evaluations of multiple AI software packages to screen and triage people with TB using chest x-rays. The team published the first-ever scientific article, evaluating the accuracy of multiple AI software for detecting TB from chest x-rays now available in Nature Scientific Reports.
Updated Cochrane Review published: Lateral flow urine lipoarabinomannan assay for detecting active TB in people living with HIV (post)
Tuberculosis (TB) causes more deaths in people living with HIV than any other disease, with more than 300,000 deaths in 2017. When detected, early TB can be treated effectively; however, people with advanced HIV are at high risk of death, often without knowing they have TB. Diagnosis of TB in HIV-positive people is often complicated because they may not present with typical symptoms, and sputum-based test are not always effective because many have disease outside the lungs and may not be able to produce sputum.
Xpert Ultra assay identifies pediatric TB with high sensitivity (post)
An updated version of the Xpert Mycobacterium tuberculosis and rifampin assay, known as Ultra, demonstrated high sensitivity in diagnosing pulmonary tuberculosis in children compared with traditional bacteriologic testing, according to research published in Pediatrics.
WHO evaluation of centralized assays for detection of TB and of resistance to rifampicin and isoniazid (post)
24 October 2019 | Geneva - The TB diagnostic pipeline has advanced significantly in the last decade, with promising tools being developed in recent years. Among the newest diagnostic tools emerging from the TB diagnostic pipeline are multi-disease high throughput centralized assays which permit upfront TB detection as well as the identification of isoniazid and rifampicin resistance. The World Health Organization convened a Technical Expert Group to assess the results of an external laboratory validation of four novel centralized TB assays: the Abbott RealTime MTB and MTB RIF/INH assays, the Roche cobas® MTB and MTB-RIF/INH assays, the Hain FluoroType® MTBDR assay, and the BD MAXTM MDR-TB assay.
WHO updates policy for the use of lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosing active TB in people living with HIV (post)
30 October 2019 | Geneva - The World Health Organization (WHO) has updated its guidance for the use of lateral flow urine lipoarabinomannan assay (LAM) in the diagnosis of tuberculosis (TB). Following new evidence, WHO now recommends a broader use of urinary LAM assays for diagnosis of TB in people living with HIV.
Low clinical value in repeat latent TB tests in patients taking biologics (post)
TLANTA — Repeat, routine testing for latent tuberculosis infection among patients receiving biologics is both costly and of low clinical value, according to findings presented at the 2019 ACR/ARP Annual Meeting.
IGRA test for latent TB infection now available through the Stop TB Partnership’s Global Drug Facility (post)
05 December 2019 I Geneva, Switzerland – The Stop TB Partnership’s Global Drug Facility (GDF) has expanded its Diagnostics Catalog by adding an IGRA (interferon-gamma release assay) test for latent TB infection. The products required to run the QuantiFERON-TB Gold Plus (QFT-Plus) IGRA are now available at a GDF-negotiated price of $15.90 per test by the manufacturer Qiagen (Hilden, Germany). This price is offered to any public sector or not-for-profit buyer in low- and middle-income countries when procuring through GDF.
WHO announces updates on new molecular assays for the diagnosis of TB and drug resistance (post)
13 January 2020 | GENEVA - Significant improvements to the diagnosis of tuberculosis (TB) and rifampicin resistance in adults and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO) in a Rapid Communication released today.
European Laboratory Initiative on TB, HIV and Viral Hepatitis sets priorities for integrated testing and diagnosis in 2020–2021 (post)
The European Laboratory Initiative on TB, HIV and Viral Hepatitis (ELI), a regional network supporting a joint, patient-centred response to the 3 diseases, has set priorities for the next 2 years to improve integrated diagnostic services.
Page 36 of 70 · Total posts: 0
←First 35 36 37 Last→